176 related articles for article (PubMed ID: 8997072)
1. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
Levine AC; Kirschenbaum A; Gabrilove JL
Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
[TBL] [Abstract][Full Text] [Related]
2. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy for benign prostatic hyperplasia in the 90's.
Ekman P
J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
[TBL] [Abstract][Full Text] [Related]
4. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
Agha AH; Roy JB; Culkin DJ; Lyon K
Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
[TBL] [Abstract][Full Text] [Related]
5. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
6. Nonsurgical treatment of prostatic hyperplasia.
Geller J
Cancer; 1992 Jul; 70(1 Suppl):339-45. PubMed ID: 1376202
[TBL] [Abstract][Full Text] [Related]
7. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin.
Boehm S; Nirnberger G; Ferrari P
Wien Klin Wochenschr; 1998 Dec; 110(23):817-23. PubMed ID: 10025034
[TBL] [Abstract][Full Text] [Related]
8. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
9. Benign prostatic hyperplasia. Hormonal treatment.
McConnell JD
Urol Clin North Am; 1995 May; 22(2):387-400. PubMed ID: 7539183
[TBL] [Abstract][Full Text] [Related]
10. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
Loran OB; Pushkar' DIu; Rasner PI
Urologiia; 2002; (1):19-22. PubMed ID: 11877966
[TBL] [Abstract][Full Text] [Related]
11. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
12. [New conservative therapeutic approaches in benign prostatic hyperplasia].
Schulze H; Berges R; Paschold K; Senge T
Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
[TBL] [Abstract][Full Text] [Related]
13. Medical management of prostatic diseases.
Schlegel PN
Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
[TBL] [Abstract][Full Text] [Related]
14. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
[TBL] [Abstract][Full Text] [Related]
15. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
Granados Loarca EA
Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
[TBL] [Abstract][Full Text] [Related]
16. [Finasteride in prolonged therapy of patients with benign prostatic hyperplasia].
Mazo EB
Urologiia; 2001; (3):20-2. PubMed ID: 11505535
[TBL] [Abstract][Full Text] [Related]
17. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
Magoha GA
East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
[TBL] [Abstract][Full Text] [Related]
18. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
19. [Benign hypertrophy of the prostate: which treatment, for whom?].
Schulman C
Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
[TBL] [Abstract][Full Text] [Related]
20. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
